TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.

Authors: Bardia, Aditya, Pusztai, Lajos, Albain, Kathy, Ciruelos, Eva Maria, Im, Seock-Ah, Hershman, Dawn, Kalinsky, Kevin, Isaacs, Claudine, Loirat, Delphine, Testa, Laura, Tokunaga, Eriko, Wu, Jiong, Dry, Hannah, Barlow, William, Kozarski, Robert, Maxwell, Micah, Harbeck, Nadia, Sharma, Priyanka

Source: Therapeutic Advances in Medical Oncology; 4/29/2024, p1-14, 14p

Spatial predictors of immunotherapy response in triple-negative breast cancer.

Authors: Wang, Xiao Qian, Danenberg, Esther, Huang, Chiun-Sheng, Egle, Daniel, Callari, Maurizio, Bermejo, Begoña, Dugo, Matteo, Zamagni, Claudio, Thill, Marc, Anton, Anton, Zambelli, Stefania, Russo, Stefania, Ciruelos, Eva Maria, Greil, Richard, Győrffy, Balázs, Semiglazov, Vladimir, Colleoni, Marco, Kelly, Catherine M., Mariani, Gabriella, Del Mastro, Lucia

Source: Nature; Sep2023, Vol. 621 Issue 7980, p868-876, 9p

Patient-Reported Outcomes in Patients With -Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.

Authors: Ciruelos, Eva Maria, Rugo, Hope S, Mayer, Ingrid A, Levy, Christelle, Forget, Frédéric, Delgado Mingorance, Juan Ignacio, Safra, Tamar, Masuda, Norikazu, Park, Yeon Hee, Juric, Dejan, Conte, Pierfranco, Campone, Mario, Loibl, Sibylle, Iwata, Hiroji, Zhou, Xiaolei, Park, Jinhee, Ridolfi, Antonia, Lorenzo, Ines, André, Fabrice

Source: Journal of Clinical Oncology; 6/20/2021, Vol. 39 Issue 18, p2005-2015, 11p

This result is not displayed to guests.
Login for full access.